Literature DB >> 27348707

Stem cell transplantation outcomes in lymphoblastic lymphoma.

Jonathan E Brammer1, Issa Khouri1, David Marin1, Celina Ledesma1, Gabriela Rondon1, Stefan O Ciurea1, Yago Nieto1, Richard E Champlin1, Chitra Hosing1, Partow Kebriaei1.   

Abstract

Lymphoblastic lymphoma (LBL) is an aggressive lymphoma pathologically similar to lymphoblastic leukemia, but primarily presents with nodal or extra-medullary involvement. The aim of this study is to describe outcomes of patients undergoing stem cell transplantation (SCT) for LBL compared to historical data. Thirty-nine patients, of which 54% lacked complete remission (CR), received SCT for LBL between 1990 and 2015; 31 allogeneic and eight autologous. Overall survival (OS) and progression free survival (PFS) at three years for the entire cohort was 41%, the cumulative incidence (CI) of non-relapse mortality (NRM) was 18% at one year, and CI relapse mortality was 28% at one-year and 36% at three years; results similar to historical reports. On multivariate analysis, the use of total-body irradiation (TBI) based conditioning and transplantation in CR were independently predictive of OS and PFS. For patients requiring SCT for LBL, CR and TBI-based conditioning prior to allogeneic SCT may provide improved disease control.

Entities:  

Keywords:  Allogeneic stem cell transplantation; autologous stem cell transplantation; clinical results; lymphoblastic lymphoma

Mesh:

Year:  2016        PMID: 27348707     DOI: 10.1080/10428194.2016.1193860

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

Review 1.  Lymphoblastic Lymphoma: a Concise Review.

Authors:  Tamara Intermesoli; Alessandra Weber; Matteo Leoncin; Luca Frison; Cristina Skert; Renato Bassan
Journal:  Curr Oncol Rep       Date:  2022-01-20       Impact factor: 5.075

2.  National survey of myeloablative total body irradiation prior to hematopoietic stem cell transplantation in Japan: survey of the Japanese Radiation Oncology Study Group (JROSG).

Authors:  Naoya Ishibashi; Toshinori Soejima; Hiroki Kawaguchi; Takeshi Akiba; Masatoshi Hasegawa; Kouichi Isobe; Hitoshi Ito; Michiko Imai; Yasuo Ejima; Masaharu Hata; Keisuke Sasai; Emiko Shimoda; Toshiya Maebayashi; Masahiko Oguchi; Tetsuo Akimoto
Journal:  J Radiat Res       Date:  2018-07-01       Impact factor: 2.724

3.  T Cell-Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation for Treatment of T-Lymphoblastic Lymphoma.

Authors:  Lixun Guan; Xiaohong Li; Huaping Wei; Zhenyang Gu; Shasha Zhao; Chengying Zhu; Nan Yang; Feiyan Wang; Lan Luo; Zhe Gao; Wenrong Huang; Honghua Li; Quanshun Wang; Daihong Liu; Xiaoxiong Wu; Chunji Gao
Journal:  Ann Transplant       Date:  2018-06-22       Impact factor: 1.530

4.  Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma.

Authors:  Luxin Yang; Yamin Tan; Jimin Shi; Yanmin Zhao; Yuanyuan Zhu; Yongxian Hu; Wenjue Pan; Yishan Ye; Jingsong He; Weiyan Zheng; Jie Sun; Zhen Cai; He Huang; Yi Luo
Journal:  Bone Marrow Transplant       Date:  2018-04-30       Impact factor: 5.483

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.